Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name KDR Q472H
Gene Variant Detail

KDR Q472H (gain of function)

Relevant Treatment Approaches VEGFR Inhibitor (Pan) VEGFR2 Inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KDR Q472H melanoma sensitive unspecified VEGFR2 antibody Preclinical Actionable In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613). 26631613
KDR Q472H melanoma sensitive VEGFR Inhibitor (Pan) Dabrafenib + Lenvatinib Preclinical - Cell culture Actionable In a preclinical study, treatment with the combination of Tafinlar (dabrafenib) and Lenvima (lenvatinib) synergistically inhibited viability of melanoma cell lines expressing KDR Q472H compared to cells expressing wild-type KDR in culture (PMID: 38201446). 38201446
KDR Q472H melanoma sensitive VEGFR Inhibitor (Pan) Dabrafenib + Lenvatinib + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Lenvima (lenvatinib) treatment to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) decreased proliferation compared to the combination alone in melanoma cell lines expressing KDR Q472H in culture (PMID: 38201446). 38201446
KDR Q472H epithelioid sarcoma predicted - sensitive VEGFR Inhibitor (Pan) Everolimus + Vandetanib Case Reports/Case Series Actionable In a Phase I trial, treatment with the combination of Afinitor (everolimus) and Caprelsa (vandetanib) was well tolerated and resulted in a median progression-free survival of 3.3 months, median overall survival of 4.6 months, clinical benefit rate of 38% in pediatric and young adult patients with advanced solid tumors, including 1 partial response in a 20 year-old patient with metastatic epithelioid sarcoma harboring germline KDR Q472H (PMID: 37879233; NCT01582191). 37879233